期刊
CURRENT UROLOGY REPORTS
卷 18, 期 11, 页码 -出版社
SPRINGER
DOI: 10.1007/s11934-017-0736-1
关键词
Ga-68-PSMA-HBED-CC; Ga-68-PSMA-11; Prostate cancer; Prostate-specific membrane antigen; PSMA; PET/CT
Purpose of the Review Recently introduced Gallium-68 labeled PSMA-ligands such as HBED-CC (Ga-68-PSMA) have shown promise for unmet diagnostic needs in prostate cancer. Recent Findings Ga-68-PSMA has demonstrated improved detection rates and specificity for prostate cancer compared to standard imaging approaches. In the setting of primary disease, Ga-68-PSMA appears to preferentially identify treatment-relevant intermediate and high-risk prostate cancer. There is also a growing evidence that Ga-68-PSMA positron emission tomography (PET) outperforms alternative conventional imaging methods including choline-based radiotracers for the localization of disease sites at biochemical recurrence, particularly at lower prostate-specific antigen (PSA) levels (< 1 ng/mL). However, the majority of published work lacks rigorous verification of imaging results. Summary Ga-68-PSMA offers significant promise for both, primary disease and biochemically recurrent prostate cancer. The evidence base to support Ga-68-PSMA is however still underdeveloped, and more rigorous studies substantiating efficacy are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据